Zomedica Corp. Files 8-K on Financials

Ticker: ZOMDF · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1684144

Zomedica Corp. 8-K Filing Summary
FieldDetail
CompanyZomedica Corp. (ZOMDF)
Form Type8-K
Filed DateApr 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, financial-statements, 8-k

TL;DR

Zomedica filed an 8-K on April 4th detailing their financial results as of April 1st.

AI Summary

Zomedica Corp. filed an 8-K on April 4, 2024, reporting results of operations and financial condition as of April 1, 2024. The filing includes financial statements and exhibits, with the company's principal executive offices located in Ann Arbor, Michigan.

Why It Matters

This 8-K filing provides investors with an update on Zomedica Corp.'s financial performance and condition, which is crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

  • Zomedica Corp. (company) — Registrant
  • April 1, 2024 (date) — Date of earliest event reported
  • April 4, 2024 (date) — Filing date
  • Ann Arbor, Michigan (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing for Zomedica Corp.?

The primary purpose is to report on Zomedica Corp.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was as of April 1, 2024.

What is the SEC file number for Zomedica Corp.?

The SEC file number for Zomedica Corp. is 001-38298.

Where are Zomedica Corp.'s principal executive offices located?

Zomedica Corp.'s principal executive offices are located at 100 Phoenix Drive, Suite 125, Ann Arbor, Michigan, 48108.

What is Zomedica Corp.'s telephone number?

Zomedica Corp.'s telephone number, including area code, is (734) 369-2555.

Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-04-04 12:10:30

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On April 1, 2024, Zomedica Corp. (the "Company") issued a press release announcing the Company's financial results for the year and quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits 99.1 Press Release, dated April 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZOMEDICA CORP. Date: April 1, 2024 By: /s/ Peter Donato Name: Peter Donato Title: Executive President and Chief Financial Officer -3- Exhibit Index 99.1 Press Release, dated April 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -4-

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.